NGM Biopharmaceuticals, Inc.: Series A $25.5M

Posted in I - Series A, Q - 1Q08, R - WEST, X - Metabolism

NGM Biopharmaceuticals (Hillsborough, CA) an early-stage drug development company focused on metabolic diseases closed a $25.5M Series A financing. Participants include Column Group, Prospect Venture Partners and Rho Ventures.

Feb

2008

Escoublac, Inc.: Series A $6.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

to top of page...